Antithrombotic Therapy for Patients Undergoing Cardiac Electrophysiological and Interventional Procedures: JACC State-of-the-Art Review.

Electrophysiological and interventional procedures have been increasingly used to reduce morbidity and mortality in patients experiencing cardiovascular diseases. Although antithrombotic therapies are critical to reduce the risk of stroke or other thromboembolic events, they can nonetheless increase the bleeding hazard. This is even more true in an aging population undergoing cardiac procedures in which the combination of oral anticoagulants and antiplatelet therapies would further increase the hemorrhagic risk. Hence, the timing, dose, and combination of antithrombotic therapies should be carefully chosen in each case. However, the maze of society guidelines and consensus documents published so far have progressively led to a hazier scenario in this setting. Aim of this review is to provide—in a single document—a quick, evidenced-based practical summary of the antithrombotic approaches used in different cardiac electrophysiology and interventional procedures to guide the busy clinician and the cardiac proceduralist in their everyday practice. [Display omitted] • Cardiac electrophysiological and other interventional procedures can usually be performed safely without interrupting (or only briefly interrupting) oral anticoagulants. • OAC can be combined with a single antiplatelet agent and is feasible in patients with AF undergoing PCI. • The long-term antithrombotic strategy should be individualized based on the balance of thromboembolic and hemorrhagic risks. [ABSTRACT FROM AUTHOR]